Newsroom | 3993 results

OXFORD, England--(BUSINESS WIRE)--Etcembly has signed a collaboration agreement with DJS Antibodies, a part of AbbVie, to accelerate the discovery of novel antibody therapeutics....

SEOUL, South Korea--(BUSINESS WIRE)--Innovo Therapeutics' INV-101 has shown positive results in a randomized, double-blind, placebo-controlled study with no serious adverse events (SAEs)....

BOSTON--(BUSINESS WIRE)--Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo therapies, today announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for its lead program EN-374 in X-linked chronic granulomatous disease (X-CGD), a rare and severe genetic disorder. EN-374 is a first-in-class in vivo hematopoietic stem cell (HSC)-directed therapy for X-CGD, which is caused by mutations in the CYBB gen...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Presents Positive Preclinical Data on ABCL575 at the SID Annual Meeting 2025...

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that, as a result of the current economic environment and other capital allocation alternatives, its Board of Directors has approved the payment of a reduced, quarterly cash dividend of $0.15 per share of common stock to be paid to its shareholders of record as of the close of business on...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (...

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the CureDuchenne FUTURES National Conference, taking place in San Antonio, TX, from May 22 to 25. Satellos Co-founder and CEO Frank Gleeson will participate in the “New Therapeutic Approaches” session on Sat., May 24 from 1:30-2:30 p.m. CT. Event and registrati...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The resubmission was classified as a Class 2 resubmission and pursuant to the Prescription Drug User Fee Act (PDUFA) has been assigned a target action date for the FDA de...

NEW YORK e PARIGI--(BUSINESS WIRE)--Owkin, importante azienda di IA agentica, ha lanciato K Navigator, un copilota di ricerca potenziato dall'intelligenza artificiale, progettato per rivoluzionare la scienza biomedica. K Navigator è un'area agentica nella quale i ricercatori possono esplorare, raffinare e convalidare ipotesi, accelerando la qualità e i tempi delle proprie scoperte. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. L...

NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, une entreprise leader dans le domaine de l’IA agentique, a lancé K Navigator, un copilote de recherche basé sur l’IA conçu pour révolutionner la science biomédicale. K Navigator est un terrain de jeu agentique où les chercheurs peuvent explorer, affiner et valider des hypothèses, accélérant ainsi la qualité et le rythme de leurs découvertes. Avec K Navigator, Owkin se rapproche de son objectif de développer la première superintelligence biologique artif...